Ideal candidates might include those who: Have documented binge eating episodes causing significant distress Meet BMI criteria for weight management medications Have not responded adequately to psychological interventions (such as cognitive behavioural therapy) Do not have contraindications to GLP-1 therapy Understand the off-label nature of this indication UK SmPCs for GLP-1 medications note findings of thyroid C-cell tumours in rodent studies, though the relevance to humans remains uncertain
(7) After the fragments have settled, discard the PBS
1 H NMR (400 MHz, DMSO) 8.74 (s, 1H), 8.22 (d, J = 8.3 Hz, 1H), 7.50 7.39 (m, 9H), 7.22 (s, 1H), 7.18 7.09 (m, 6H), 6.91 (t, J = 6.0 Hz, 1H), 4.57 (td, J = 9.0, 4.8 Hz, 1H), 3.50 (d, J = 10.9 Hz, 2H), 3.14 (dd, J = 15.0, 4.9 Hz, 1H), 2.94 (dd, J = 15.0, 9.8 Hz, 1H), 1.34 (s, 9H)
Outcomes track adherence to the prescribed regimen
Who is an Ideal Candidate for PT-141
Long-term cardiovascular safety wont be confirmed until TRIUMPH-CVOT reports, expected in 2028 at the earliest